DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study Evaluating Enbrel in Adults With Active Rheumatoid Arthritis in Luxemburg

Information source: Wyeth
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: etanercept (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Wyeth

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Wyeth

Overall contact:
Pfizer CT.gov Call Center 1-800-718-1021, Email: ClinicalTrials.gov_Inquiries@pfizer.com

Summary

The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.

Clinical Details

Official title: A Post-marketing Surveillance Looking at Safety and Adherence to Treatment of Enbrel in Adults With Active Rheumatoid Arthritis in Luxemburg

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: To determine the long term safety of Enbrel in adults with active rheumatoid arthritis.

Secondary outcome:

To determine the percentage of adult patients with RA that stay on a treatment with Enbrel

To determine the effect of Enbrel on number of joints with active synovitis and quality of life as measured by HAQ when treatment is provided in daily practice.

To determine the possible reduction/elimination of concomitant medications (MTX/steroids) in RA and JRA

Eligibility

Minimum age: 17 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Have moderate to severe active rheumatoid arthritis

- Be aged of 17 years or more

- Have inadequate response to DMards

- Give written informed consent

- Physician decides to prescribe Enbrel

Locations and Contacts

Pfizer CT.gov Call Center 1-800-718-1021, Email: ClinicalTrials.gov_Inquiries@pfizer.com

Esch-sur-Alzette L-4243, Luxembourg; Recruiting

Esch-sur-Alzette L-4170, Luxembourg; Not yet recruiting

Luxembourg L-2420, Luxembourg; Recruiting

Luxembourg L-1361, Luxembourg; Not yet recruiting

Luxembourg L-1611, Luxembourg; Recruiting

Luxembourg L-2449, Luxembourg; Not yet recruiting

Niedercorn (Differdange) L-4602, Luxembourg; Recruiting

Additional Information

Starting date: February 2003
Last updated: March 31, 2010

Page last updated: October 04, 2010

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014